$RENB News
Last published 1y ago
- 1y agoRENBLNAILunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and BiodefenseACCESS NewswireLOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Lunai Bioworks Inc. , a pioneer in AI-powered drug discovery and biodefense, today announced the formal adoption of its new corporate
- 1y agoRENBLunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma PartnershipsACCESS NewswireNEW YORK CITY, NEW YORK / ACCESS Newswire / September 25, 2025 / Lunai Bioworks Inc.
- 1y agoRENBLunai Bioworks, Inc. to Effect 10:1 Reverse Stock SplitACCESS NewswireMeasure taken to Comply with Nasdaq Rule 5550 Regarding Minimum Bid Price LOS ANGELES, CA / ACCESS Newswire / September 24, 2025 / Lunai Bioworks, Inc. ("Lunai Bioworks" or the
- 1y agoRENBLunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder TherapeuticsACCESS NewswireBETHESDA, MD / ACCESS Newswire / September 11, 2025 / Lunai Bioworks Inc.'s wholly-owned subsidiary BioSymetrics Inc. today announced the award of a prestigious Small Business Technology Transfer
- 1y agoRENBLunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug DiscoveryACCESS NewswireProprietary safety intelligence creates dual value: faster therapeutic development and biodefense. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 9, 2025 / Lunai Bioworks Inc. , an AI-powered drug
- 1y agoRENBLunai Bioworks Strengthens European Strategy Through RestructuringACCESS NewswireCompany remains committed to Europe with a streamlined, growth-focused approach. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 8, 2025 / Lunai Bioworks Inc. , an AI-powered drug discovery and
- 1y agoRENBLunai Bioworks Inc. Retains American Defense InternationalACCESS NewswireCollaboration aims to apply Lunai Bioworks Inc. biomedical AI platform to accelerate countermeasure development for chemical agents like sarin and other biothreats LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 4,
- 1y agoRENBRenovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced DiagnosticsACCESS NewswireLOS ANGELES, CALIFORNIA / ACCESS Newswire / August 27, 2025 / Renovaro Inc. today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and
- 1y agoRENBRenovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense RisksACCESS NewswireLOS ANGELES, CALIFORNIA / ACCESS Newswire / August 8, 2025 / Renovaro Inc. was referenced in a recent RealClearDefense article titled "AI Can Be Used to Develop Biological and Chemical Weapons",
- 1y agoRENBHCTIGEHCMDAIAI Just Got a Green Light from the White House--Here's What That Means for Healthcare StocksPR NewswireEquity Insider News Commentary – There's a lot of big voices pushing for the AI revolution to make its mark, including a new plan from the U.S....
- 1y agoRENBRenovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI SectorACCESS NewswireStrategic IP expansion protects federated learning technology driving pharma partnerships, biosecurity initiatives, and precision medicine growth LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 28, 2025 / Renovaro
- 1y agoRENBPeer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor EfficacyACCESS NewswireLandmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro Biosciences
- 1y agoRENBRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security NeedsACCESS NewswireLOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify
- 1y agoRENBGOOGGOOGLOMDA+1Smart Healthcare Is Taking Over. Here's Where the Money's HeadedPR NewswireBoth politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent...
- 1y agoRENBRenovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics PlatformGlobeNewswireExpanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a clinical-stage
- 1y agoRENBCERTCCLDMSFTAI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the ChargePR NewswireEquity Insider News Commentary – A new report from Philips reveals a growing divide between doctors and patients when it comes to AI in healthcare....
- 1y agoPOAIRENBUPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyGlobeNewswireLOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has
- 1y agoPOAIRENBRenovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive OncologyGlobeNewswireLOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has
- 1y agoRENBRenovaro Launches Augusta, an AI-Powered Precision Neurology PlatformGlobeNewswireNew Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro
- 1y agoRENBRenovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA DiagnosticsGlobeNewswireLOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for
- 1y agoRENBRenovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic ProgramsGlobeNewswireLOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients,
- 1y agoRENBRenovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision MedicineGlobeNewswireStrategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences
- 1y agoPOAIRENBRenovaro Provides Update to Definitive Agreement with Predictive OncologyGlobeNewswireLOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today
- 1y agoPOAIRENBRenovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive OncologyGlobeNewswireCompany Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States Renovaro's
- 1y agoPOAIRENBPredictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro BiosciencesGlobeNewswirePredictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States Renovaro's recent
- 1y agoRENBRenovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision MedicineGlobeNewswireStrategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro
- 1y agoRENBRenovaro Announces $15 million in Equity CommittedGlobeNewswireLOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announces that it has $15 million in additional
- 1y agoONCYGRALDGXRENB+1Investors Eye Biotech Sector as Cancer Therapy Market SurgesPR NewswireUSA News Group News Commentary – Amid the excitement surrounding Project Stargate—the $500 billion investment aimed at revolutionizing AI-driven data ...
- 1y agoRENBRenovaro Appoints Nathen Fuentes as Chief Financial OfficerGlobeNewswireSenior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc.
- 1y agoPOAIRENBRenovaro Issues Shareholder Letter and Provides Corporate UpdateGlobeNewswireCompany to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial
- 1y agoPOAIRENBRenovaro to Acquire Predictive Oncology in All-Stock TransactionGlobeNewswireAcquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical
- 1y agoPOAIRENBPredictive Oncology Announces Agreement to be Acquired by RenovaroGlobeNewswire- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders' interest, augment
- 1y agoRENBRenovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BVGlobeNewswireCurrent Renovaro Chairman to Lead Subsidiary's Development Program and Commercialization LOS ANGELES and AMSTERDAM, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and
- 1y agoRENBRenovaroCube Receives Approval of Lumina Project by the Eurostars Funding ProgramGlobeNewswireLUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI LOS ANGELES and AMSTERDAM, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc.
- 1y agoRENBRenovaro Regains Compliance with NASDAQ Listing RequirementGlobeNewswireLOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced that it has received a notice from the
- 1y agoRENBRenovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease DetectionGlobeNewswireRenovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a
- 2y agoRENBRenovaro Issues Shareholder Letter and Provides Corporate UpdateGlobeNewswireLOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief
- 2y agoRENBRenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore SequencingGlobeNewswireAMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest
- 2y agoRENBRenovaro Announces Strategic Restructuring and Leadership TransitionGlobeNewswireSupermajority of Shareholders Support Appointment of New CEO and the Replacement of Entire Board of Directors with Full Five-Member SlateRealignment of Resources to Optimize and Commercialize RenovaroCube, the Company's
- 2y agoRENBPersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care DiagnosticsGlobeNewswireAMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube's AI-driven, multi-omic platform
- 2y agoRENBIndependent Expert Assessment Validates RenovaroCube's Potential as a Groundbreaking AI Platform Starting with Early Cancer DetectionGlobeNewswireAMSTERDAM, Sept. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) - PersonalAIze, a cutting-edge company in AI and machine learning applications for healthcare, has conducted a comprehensive evaluation of RenovaroCube's
- 2y agoRENBRenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology CongressGlobeNewswireAMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific
- 2y agoRENBRenovaroCube Announces Strategic Offering of Up to 20% OwnershipGlobeNewswireAMSTERDAM, Sept. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RENB) The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of RenovaroCube (Cube), currently a wholly owned subsidiary. This
- 2y agoRENBRenovaro, Inc. Announces $10 million in Equity CommittedGlobeNewswireLOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- Renovaro, Inc. (NASDAQ:RENB) (the "Company") announces that it has $10 million in additional equity committed at a price per share of $1.4726 and 10 percent warrant
- 2y agoRENBRenovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer ImmunotherapyGlobeNewswireLOS ANGELES and AMSTERDAM, May 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint
- 2y agoABBVCYTOONCYPFE+1Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032GlobeNewswirePALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis,
- 2y agoRENBTransforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on FragmentomicsGlobeNewswireLOS ANGELES and AMSTERDAM, April 30, 2024 (GLOBE NEWSWIRE) -- RenovaroCube, wholly owned subsidiary of Renovaro, Inc. (NASDAQ:RENB), a company at the forefront of AI-driven healthcare innovation, proudly unveils
- 2y agoRENBRenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics PartnershipGlobeNewswireLOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation
- 2y agoRENBRenovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient CareGlobeNewswireLOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor
- 2y agoRENBCutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplaceGlobeNewswireA Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single vial of